Explore more Johnson & Johnson sites:
Press Release Archive
-
U.S. FDA Extends Review Timeline for INVOKANA® (canagliflozin) Supplemental New Drug ApplicationU.S. FDA Extends Review Timeline for INVOKANA® (canagliflozin) Supplemental New Drug Application
-
Johnson & Johnson’s Official Statement in Response to Today’s Verdict in St. Louis TrialJohnson & Johnson’s Official Statement in Response to Today’s Verdict in St. Louis Trial
-
Janssen Provides Update on IMBRUVICA® (ibrutinib) Phase 3 PHOENIX Trial in Newly Diagnosed Non-Germinal Center B Cell (Non-GCB) Subtype of Diffuse Large B-Cell Lymphoma (DLBCL)Janssen Provides Update on IMBRUVICA® (ibrutinib) Phase 3 PHOENIX Trial in Newly Diagnosed Non-Germinal Center B Cell (Non-GCB) Subtype of Diffuse Large B-Cell Lymphoma (DLBCL)
-
Johnson & Johnson Announces Publication in The Lancet Highlighting Robust Immune Response to Janssen’s Mosaic-based Preventive Vaccine Regimen for HIVJohnson & Johnson Announces Publication in The Lancet Highlighting Robust Immune Response to Janssen’s Mosaic-based Preventive Vaccine Regimen for HIV
-
Champions of Science: The Art of Ending Stigma Project Launches to Combat Stigma About Mental Illnesses Through Education and Artistic CreationChampions of Science: The Art of Ending Stigma Project Launches to Combat Stigma About Mental Illnesses Through Education and Artistic Creation
-
Real-World Study of More than 700,000 People with Type 2 Diabetes (T2D) Shows No Increased Risk of Below-Knee Lower Extremity Amputations with INVOKANA® (canagliflozin) Compared to Other Diabetes MedicationsReal-World Study of More than 700,000 People with Type 2 Diabetes (T2D) Shows No Increased Risk of Below-Knee Lower Extremity Amputations with INVOKANA® (canagliflozin) Compared to Other Diabetes Medications
-
Real-World Evidence Shows Oral INVOKANA® (canagliflozin) Results in Greater Weight Loss and Treatment Adherence Than Injectable GLP-1 Receptor Agonists in Type 2 Diabetes PatientsReal-World Evidence Shows Oral INVOKANA® (canagliflozin) Results in Greater Weight Loss and Treatment Adherence Than Injectable GLP-1 Receptor Agonists in Type 2 Diabetes Patients
-
Johnson & Johnson Announces Retirement of Group Worldwide Chairman, Sandra E. PetersonJohnson & Johnson Announces Retirement of Group Worldwide Chairman, Sandra E. Peterson
-
Johnson & Johnson Appoints Senior Leaders to Executive CommitteeJohnson & Johnson Appoints Senior Leaders to Executive Committee
-
Johnson & Johnson to Host Investor Conference Call on Second-Quarter ResultsJohnson & Johnson to Host Investor Conference Call on Second-Quarter Results